IBO (impactbiomedinc.com) Return on Gross Profit

Official company branding of impactbiomedinc.com (IBO)

Impact BioMedical Inc (IBO) possesses moderate pricing power in the biosafety segment due to patents on plant-based compositions. The gross margin percentage reflects operational efficiency, with the current figure standing at -4026.30. The company is expanding its intellectual property system, planning strategic partnerships by 2026. Business growth is driven by the commercialization of the 3F repellent and the sale of technology licenses.

impactbiomedinc.com (IBO) - Return on Gross Profit from 09/17/2024 to 11/19/2026

Financial and market metric breakdowns for Impact BioMedical, Inc. (IBO)

- market value and analyst target forecast:
Basic company analysis:IBO Impact BioMedical, Inc.
Finished products of Impact BioMedical

Conservative capital demands transparency in cost structures to assess business resilience to inflationary shocks. This indicator measures the profit margin after deducting direct production costs, determining the efficiency of cost management and the company's pricing power. For Impact BioMedical Inc (IBO), a high gross profit margin confirms low patent licensing costs and high profitability of royalties from biomedical developments.

Main competitors

Gross Profit Margin Haleon PLC (HLN)|Return on Gross Profit KVUE|Gross Profit Margin Verona Pharma Inc. VRNA|Gross Margin MENS|Ligand Pharmaceuticals - Gross Return on Sales|Gross Profitability Amneal AMRX|Gross Sales Margin Perrigo Company PLC|Alvotech Biopharmaceuticals - Gross Margin|Return on Sales by Gross Profit Liquidia Technologies LQDA|Galapagos N.V. (GLPG) - Gross Profitability|anipharmaceuticals.com - Gross Profit Rate|Return on Gross Profit MNKD|AMPH: Gross Profit Rate|Gross Profitability pacira.com (PCRX)|Gross Margin ARS Pharma (SPRY)|Theravance Biopharma - Return on Gross Profit|Gross Profit Ratio AQST (Aquestive Therapeutics)|SCPH: Return on Gross Profit|Gross Profit Margin Tectonic Therapeutic|TNXP: Gross Margin|SXT China (SXTC) - Gross Margin|Gross Profitability eupraxiapharma.com|BioHarvest Sciences (BHST) - Return on Sales by Gross Profit|Gross Profitability Invizyne (EXOZ)|ORMP - Gross Profit Margin|Gross Margin ENTX (Entera Bio)|Gross Sales Margin MindWalk Therapeutics|ABVC: Return on Gross Profit|CPIX - Gross Margin|QNTM (Quantum BioPharma) - Return on Gross Profit|Gross Profitability Margin FGEN (FibroGen)|TELO (Telomir Pharmaceuticals Corp) - Gross Margin|Gross Margin ranitherapeutics.com|Gross Profitability Synergy CHC Corp. (SNYR)|Rallybio Corp - Gross Return on Sales|lexariabioscience.com - Return on Gross Profit|Gross Margin Pulmatrix Inc PULM|Pheton Holdings - Gross Margin|Gross Profitability Margin APM|Lyra Therapeutics, Inc. (LYRA) - Gross Profitability|TNF Pharma (TNFA) - Gross Margin|YCBD (cbdmd.com) - Gross Margin|Return on Gross Profit PainReform (PRFX)|Gross Profitability Altamira Therapeutics (CYTO)|Return on Sales by Gross Profit Lipella Pharma|Optinose - Return on Gross Profit|Return on Sales by Gross Profit pieris.com (PIRS)|PROC - Gross Profitability|Gross Profitability Margin PTPI|QLI: Gross Margin|Gross Profit Margin ACELYRIN Inc. (SLRN)|TFFP (TFF Pharmaceuticals, Inc) - Gross Margin